Related Experiment Video
Updated: Aug 16, 2026

Gene Transfer for Ischemic Heart Failure in a Preclinical Model
Published on: May 15, 2011
HVJ-based non-viral gene transfer method: successful gene therapy using HGF and VEGF genes in experimental ischemia
Munehisa Shimamura1, Naoyuki Sato, Shinichi Yoshimura
1Division of Clinical Gene Therapy, Graduate School of Medicine, Osaka University, Japan.
Abstract:
VEGF and HGF are pleiotropic factors that regulate cell growth, cell motility, and morphogenesis of various types of cells. The receptors of these growth factors are expressed in neurons and endothelial cells, and are identified as neurotrophic, neuroprotective, and angiogenic factors. Indeed, gene therapy using viral vectors encoding the VEGF or HGF gene has been reported to be effective for preventing the expansion of ischemic injury. However, the safety issue of viral vectors is a major problem in clinical application. To overcome this problem, we have developed an HVJ-based non-viral vector, which achieves high-efficiency transfection rates of viral vectors with the safety of liposomes. This review discusses the feasibility of gene therapy using an HVJ-based non-viral vector containing the VEGF or HGF gene for cerebral ischemia.

